Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US20090305259: Early Diagnosis of Congenital Abnormalities in the Offspring of Diabetic Mothers

Share

Filing Information

Inventor(s) Joseph Madri · Anjali Nath · Michael Krauthammer · Michael Snyder · Eugene Davidov ·
Assignee(s) YALE UNIVERSITY ·
Correspondent DRINKER BIDDLE & REATH;ATTN: INTELLECTUAL PROPERTY GROUP ·
Application Number US12281767
Filing date 03/21/2007
PCT 371 date 07/21/2009
Publication date 12/10/2009
Predicted expiration date 03/21/2027
U.S. Classifications 435/6  · 435/23  · 435/14  · 435/792  · 435/29  · 435/71  ·
International Classifications C12Q102  · C12Q137  · C12Q154  · C12Q168  · G01N3300  · G01N3353  ·
Kind CodeA1
PCT Application Number WO20PCTUS2007006966 - 03/21/2007
61 Claims, 20 Drawings


Abstract

The present invention relates to the identification of a series of biomarkers, the detection of which is prognostic for women at risk of becoming hyperglycemic during pregnancy and/or fetuses at risk of developing congenital anomalies as a result of maternal hyperglycemia.

Independent Claims | See all claims (61)

  1. 1. A method of identifying a pregnant female whose fetus is at risk of developing a congenital abnormality, said method comprising measuring in a body sample obtained from said female the level of at least one biomarker, wherein when the level of said biomarker in said sample indicates that said biomarker is dysregulated in said female, said fetus is at risk for developing said congenital abnormality.
  2. 13. A method of identifying a pregnant female whose is at risk of developing hyperglycemia during pregnancy, said method comprising measuring in a body sample obtained from said female the level of at least one biomarker, wherein when the level of said biomarker in said sample indicates that said biomarker is dysregulated in said female; said female is at risk for developing hyperglycemia.
  3. 23. A method of identifying an individual whose is at risk of developing hyperglycemia, said method comprising measuring in a body sample obtained from said individual the level of at least one biomarker, wherein when the level of said biomarker in said sample indicates that said biomarker is dysregulated in said individual, said individual is at risk for developing hyperglycemia.
  4. 32. A composition comprising a plurality of oligonucleotides attached to a substrate surface, wherein each of said oligonucleotides is a nucleic acid encoding a biomarker or a fragment thereof, or is complementary to said biomarker or said fragment thereof, wherein said biomarker is selected from the group consisting of a matrix metalloproteinase, a receptor, a ligand, a transcription factor, a protein affecting apoptosis, a cytoskeletal protein, a cell adhesion molecule, actin, and a mictotubule protein, an enzyme, a metabolite associated with glucose metabolism, and a metabolite associated with diabetes.
  5. 35. A composition comprising a plurality of peptides attached to a substrate surface, wherein each of said peptides is a biomarker or a fragment thereof, wherein said biomarker is selected from the group consisting of a matrix metalloproteinase, a receptor, a ligand, a transcription factor, a protein affecting apoptosis, a cytoskeletal protein, a cell adhesion molecule, actin, a mictotubule protein, an enzyme, a metabolite associated with glucose metabolism, and a metabolite associated with diabetes.
  6. 38. A composition comprising a plurality of antibodies attached to a substrate surface wherein said antibody specifically binds a biomarker or a fragment thereof, wherein said biomarker is selected from the group consisting of a matrix metalloproteinase, a receptor, a ligand, a transcription factor, a protein affecting apoptosis, a cytoskeletal protein, a cell adhesion molecule, actin, a mictotubule protein, an enzyme, a metabolite associated with glucose metabolism, and a metabolite associated with diabetes.
  7. 41. The composition of 38, wherein at least one of said antibodies is attached to said substrate surface.
  8. 45. A kit comprising a composition for detecting the level of a biomarker in a body sample obtained from a mammal, wherein when the level of said biomarker in said sample indicates that said biomarker is dysregulated in said individual, said individual is at risk of developing hyperglycemia, and wherein said composition comprises at least one antibody that specifically binds said biomarker or a fragment thereof, said kit further comprising instructional material for the use thereof.
  9. 54. A kit comprising a composition for detecting the level of a biomarker in a body sample obtained from a mammal, wherein when the level of said biomarker in said sample indicates that said biomarker is dysregulated in said individual, said individual is at risk of developing hyperglycemia, and wherein the composition comprises at least one nucleic acid, wherein said nucleic acid encodes said biomarker or a fragment thereof, or is complementary to said biomarker or a fragment thereof, said kit further comprising an instructional material for the use thereof.
  10. 57. The kit of claim if 56, wherein said female is pregnant.

References Cited

The current document has no citations.

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.